We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
FMOD is not prognostic in Glioblastoma Multiforme (TCGA)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
58.2
Number of samples
141
Samples
Sample
Description
TPM
TCGA-28-5220-01A
0 years, male, white, stage:'--, dead, 388 days
1290.3
TCGA-32-2632-01A
0 years, male, white, stage:'--, dead, 269 days
1169.2
TCGA-28-5218-01A
0 years, male, white, stage:'--, dead, 157 days
609.1
TCGA-14-0871-01A
0 years, female, white, stage:'--, dead, 880 days
329.8
TCGA-32-4213-01A
0 years, female, white, stage:'--, alive, 604 days
262.3
TCGA-06-0210-01A
0 years, female, white, stage:'--, dead, 225 days
203.8
TCGA-28-5209-01A
0 years, female, white, stage:'--, alive, 442 days
182.6
TCGA-06-2569-01A
0 years, female, black or african american, stage:'--, alive, 13 days
180.5
TCGA-32-1982-01A
0 years, female, white, stage:'--, dead, 142 days
151.6
TCGA-06-0750-01A
0 years, male, white, stage:'--, dead, 28 days
140.3
TCGA-14-0789-01A
0 years, male, white, stage:'--, dead, 342 days
122.3
TCGA-06-5412-01A
0 years, female, white, stage:'--, dead, 138 days
96.4
TCGA-06-5416-01A
0 years, female, white, stage:'--, alive, 204 days
94.9
TCGA-06-5408-01A
0 years, female, white, stage:'--, dead, 357 days
87.8
TCGA-76-4932-01A
0 years, female, white, stage:'--, dead, 1458 days
86.1
TCGA-27-1835-01A
0 years, female, white, stage:'--, dead, 648 days
85.0
TCGA-32-5222-01A
0 years, male, white, stage:'--, dead, 585 days
84.8
TCGA-06-2557-01A
0 years, male, black or african american, stage:'--, dead, 33 days
84.0
TCGA-06-0190-01A
0 years, male, white, stage:'--, dead, 317 days
82.7
TCGA-27-1837-01A
0 years, male, white, stage:'--, dead, 427 days
76.1
TCGA-26-5132-01A
0 years, male, white, stage:'--, alive, 286 days
70.2
TCGA-06-2567-01A
0 years, male, white, stage:'--, dead, 133 days
69.3
TCGA-06-1804-01A
0 years, female, white, stage:'--, dead, 414 days
67.8
TCGA-06-2565-01A
0 years, male, asian, stage:'--, dead, 506 days
65.7
TCGA-27-2528-01A
0 years, male, white, stage:'--, dead, 480 days
62.9
TCGA-28-1753-01A
0 years, male, white, stage:'--, alive, 37 days
62.7
TCGA-06-2561-01A
0 years, female, white, stage:'--, dead, 537 days
62.7
TCGA-27-1834-01A
0 years, male, white, stage:'--, dead, 1233 days
58.3
TCGA-06-5413-01A
0 years, male, white, stage:'--, alive, 268 days
55.6
TCGA-06-0157-01A
0 years, female, white, stage:'--, dead, 97 days
54.2
TCGA-14-0817-01A
0 years, female, white, stage:'--, dead, 164 days
52.0
TCGA-27-1832-01A
0 years, female, white, stage:'--, dead, 300 days
50.8
TCGA-06-0743-01A
0 years, male, white, stage:'--, dead, 803 days
50.4
TCGA-27-1830-01A
0 years, male, white, stage:'--, dead, 154 days
48.6
TCGA-28-5207-01A
0 years, male, white, stage:'--, dead, 343 days
48.2
TCGA-06-0882-01A
0 years, male, white, stage:'--, dead, 632 days
48.2
TCGA-14-1823-01A
0 years, female, white, stage:'--, dead, 543 days
46.5
TCGA-76-4931-01A
0 years, female, white, stage:'--, dead, 279 days
44.0
TCGA-28-2513-01A
0 years, female, white, stage:'--, alive, 222 days
43.0
TCGA-12-0821-01A
0 years, male, white, stage:'--, dead, 323 days
42.7
TCGA-76-4929-01A
0 years, female, white, stage:'--, dead, 111 days
42.4
TCGA-26-5139-01A
0 years, female, white, stage:'--, alive, 48 days
41.8
TCGA-28-5208-01A
0 years, male, white, stage:'--, dead, 544 days
40.1
TCGA-12-0619-01A
0 years, male, white, stage:'--, dead, 1062 days
39.7
TCGA-19-4065-01A
0 years, male, white, stage:'--, alive, 214 days
39.3
TCGA-12-3650-01A
0 years, male, white, stage:'--, dead, 333 days
37.8
TCGA-06-2559-01A
0 years, male, white, stage:'--, dead, 150 days
37.5
TCGA-28-5216-01A
0 years, male, white, stage:'--, alive, 415 days
37.5
TCGA-12-3652-01A
0 years, male, white, stage:'--, dead, 1062 days
36.8
TCGA-06-0130-01A
0 years, male, white, stage:'--, dead, 394 days
35.3
TCGA-06-0878-01A
0 years, male, white, stage:'--, alive, 218 days
33.7
TCGA-06-0644-01A
0 years, male, black or african american, stage:'--, dead, 384 days
33.7
TCGA-06-0187-01A
0 years, male, white, stage:'--, dead, 828 days
32.9
TCGA-19-2625-01A
0 years, female, white, stage:'--, dead, 124 days
32.7
TCGA-06-0125-01A
0 years, female, white, stage:'--, dead, 1448 days
32.6
TCGA-06-2564-01A
0 years, male, white, stage:'--, alive, 181 days
32.3
TCGA-14-1034-01A
0 years, female, stage:'--, dead, 485 days
30.9
TCGA-02-0055-01A
0 years, female, white, stage:'--, dead, 76 days
30.6
TCGA-06-0156-01A
0 years, male, white, stage:'--, dead, 178 days
30.2
TCGA-27-1831-01A
0 years, male, white, stage:'--, dead, 505 days
30.1
TCGA-06-5856-01A
0 years, male, white, stage:'--, dead, 114 days
29.4
TCGA-28-5215-01A
0 years, female, white, stage:'--, dead, 335 days
27.1
TCGA-32-1970-01A
0 years, male, white, stage:'--, dead, 468 days
25.9
TCGA-32-1980-01A
0 years, male, white, stage:'--, dead, 36 days
25.0
TCGA-06-2562-01A
0 years, male, white, stage:'--, dead, 382 days
24.7
TCGA-06-0745-01A
0 years, male, white, stage:'--, dead, 239 days
24.6
TCGA-06-0211-01A
0 years, male, white, stage:'--, dead, 360 days
24.1
TCGA-41-5651-01A
0 years, female, black or african american, stage:'--, dead, 460 days
23.5
TCGA-27-2524-01A
0 years, male, white, stage:'--, dead, 231 days
23.1
TCGA-06-5418-01A
0 years, female, white, stage:'--, dead, 83 days
22.1
TCGA-06-5410-01A
0 years, female, white, stage:'--, dead, 108 days
22.0
TCGA-06-0645-01A
0 years, female, white, stage:'--, dead, 175 days
21.9
TCGA-06-0132-01A
0 years, male, white, stage:'--, dead, 771 days
21.5
TCGA-06-0141-01A
0 years, male, white, stage:'--, dead, 313 days
21.4
TCGA-28-2514-01A
0 years, male, asian, stage:'--, alive, 160 days
20.9
TCGA-76-4927-01A
0 years, male, white, stage:'--, dead, 535 days
20.4
TCGA-08-0386-01A
0 years, male, white, stage:'--, dead, 548 days
20.3
TCGA-41-4097-01A
0 years, female, white, stage:'--, dead, 6 days
20.1
TCGA-06-0749-01A
0 years, male, black or african american, stage:'--, dead, 82 days
20.0
TCGA-14-0787-01A
0 years, male, asian, stage:'--, dead, 68 days
19.1
TCGA-06-5859-01A
0 years, male, white, stage:'--, alive, 139 days
17.4
TCGA-06-2563-01A
0 years, female, white, stage:'--, alive, 932 days
16.7
TCGA-06-0139-01A
0 years, male, white, stage:'--, dead, 362 days
15.9
TCGA-41-3915-01A
0 years, male, white, stage:'--, dead, 360 days
15.4
TCGA-06-0174-01A
0 years, male, white, stage:'--, dead, 98 days
15.3
TCGA-06-0219-01A
0 years, male, white, stage:'--, dead, 22 days
14.9
TCGA-28-2509-01A
0 years, female, white, stage:'--, alive, 145 days
14.4
TCGA-27-2521-01A
0 years, male, white, stage:'--, dead, 510 days
14.0
TCGA-06-5414-01A
0 years, male, white, stage:'--, alive, 273 days
13.9
TCGA-12-5299-01A
0 years, female, white, stage:'--, dead, 98 days
13.8
TCGA-32-2615-01A
0 years, male, white, stage:'--, dead, 485 days
13.5
TCGA-32-2634-01A
0 years, male, white, stage:'--, alive, 693 days
13.3
TCGA-06-0646-01A
0 years, male, white, stage:'--, dead, 175 days
13.3
TCGA-32-2638-01A
0 years, male, white, stage:'--, dead, 766 days
12.8
TCGA-28-5204-01A
0 years, male, white, stage:'--, dead, 454 days
12.8
TCGA-19-2624-01A
0 years, male, white, stage:'--, dead, 5 days
12.5
TCGA-14-1829-01A
0 years, male, black or african american, stage:'--, alive, 218 days
12.2
TCGA-12-0616-01A
0 years, female, white, stage:'--, dead, 448 days
12.2
TCGA-27-2519-01A
0 years, male, white, stage:'--, dead, 550 days
11.9
TCGA-14-2554-01A
0 years, female, white, stage:'--, dead, 532 days
11.9
TCGA-41-2572-01A
0 years, male, white, stage:'--, dead, 406 days
11.3
TCGA-06-0158-01A
0 years, male, white, stage:'--, dead, 329 days
10.6
TCGA-06-5858-01A
0 years, female, white, stage:'--, alive, 187 days
10.6
TCGA-26-5134-01A
0 years, male, white, stage:'--, alive, 167 days
10.4
TCGA-19-2629-01A
0 years, male, white, stage:'--, dead, 737 days
10.1
TCGA-06-0138-01A
0 years, male, white, stage:'--, dead, 737 days
10.1
TCGA-06-0744-01A
0 years, male, white, stage:'--, dead, 1426 days
10.0
TCGA-06-5411-01A
0 years, male, white, stage:'--, dead, 254 days
9.8
TCGA-02-2485-01A
0 years, male, black or african american, stage:'--, alive, 470 days
9.8
TCGA-06-0747-01A
0 years, male, white, stage:'--, dead, 82 days
9.0
TCGA-02-2486-01A
0 years, male, white, stage:'--, dead, 618 days
9.0
TCGA-06-2558-01A
0 years, female, white, stage:'--, dead, 380 days
8.6
TCGA-76-4925-01A
0 years, male, white, stage:'--, dead, 146 days
8.5
TCGA-14-1825-01A
0 years, male, white, stage:'--, dead, 232 days
8.0
TCGA-26-5135-01A
0 years, female, white, stage:'--, dead, 270 days
8.0
TCGA-27-2523-01A
0 years, male, white, stage:'--, dead, 489 days
7.8
TCGA-12-0618-01A
0 years, male, white, stage:'--, dead, 395 days
7.7
TCGA-06-0686-01A
0 years, male, white, stage:'--, dead, 432 days
7.5
TCGA-16-0846-01A
0 years, male, white, stage:'--, dead, 119 days
6.8
TCGA-06-0238-01A
0 years, male, white, stage:'--, dead, 405 days
6.6
TCGA-19-2620-01A
0 years, male, white, stage:'--, dead, 148 days
6.3
TCGA-06-0184-01A
0 years, male, white, stage:'--, dead, 2126 days
6.1
TCGA-06-5417-01A
0 years, female, white, stage:'--, alive, 155 days
5.8
TCGA-26-5133-01A
0 years, male, white, stage:'--, alive, 452 days
5.7
TCGA-19-5960-01A
0 years, male, white, stage:'--, dead, 455 days
5.5
TCGA-06-0168-01A
0 years, female, white, stage:'--, dead, 598 days
5.1
TCGA-27-2526-01A
0 years, female, white, stage:'--, dead, 87 days
4.8
TCGA-15-0742-01A
0 years, male, white, stage:'--, dead, 419 days
3.4
TCGA-32-2616-01A
0 years, female, white, stage:'--, dead, 224 days
3.2
TCGA-12-3653-01A
0 years, female, white, stage:'--, dead, 442 days
2.9
TCGA-15-1444-01A
0 years, male, white, stage:'--, dead, 1537 days
2.7
TCGA-06-0178-01A
0 years, male, white, stage:'--, dead, 2681 days
2.4
TCGA-26-1442-01A
0 years, male, white, stage:'--, alive, 953 days
2.3
TCGA-12-5295-01A
0 years, female, white, stage:'--, dead, 454 days
2.2
TCGA-41-2571-01A
0 years, male, white, stage:'--, dead, 26 days
2.1
TCGA-02-0047-01A
0 years, male, white, stage:'--, dead, 448 days
2.0
TCGA-19-1390-01A
0 years, female, white, stage:'--, dead, 772 days
2.0
TCGA-19-2619-01A
0 years, female, black or african american, stage:'--, alive, 294 days
1.5
TCGA-02-2483-01A
0 years, male, asian, stage:'--, alive, 466 days
1.3
TCGA-06-2570-01A
0 years, female, white, stage:'--, alive, 958 days
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
FMOD is potential prognostic, high expression is unfavorable in Glioblastoma Multiforme (validation)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
9.5
Number of samples
58
Samples
Sample
Description
TPM
AK006
N, NA, stage:NA, dead, 360 days
48.4
AK153
N, NA, stage:NA, dead, 240 days
48.3
AK218
N, NA, stage:NA, dead, 180 days
33.3
AK089
N, NA, stage:NA, dead, 330 days
29.3
AK133
N, NA, stage:NA, dead, 360 days
29.3
AK188
N, NA, stage:NA, alive, 420 days
22.8
AK081
N, NA, stage:NA, dead, 180 days
20.0
AK098
N, NA, stage:NA, dead, 660 days
19.9
AK226
N, NA, stage:NA, dead, 360 days
19.4
AK117
N, NA, stage:NA, dead, 210 days
18.8
AK030
N, NA, stage:NA, dead, 120 days
18.6
AK195
N, NA, stage:NA, dead, 390 days
17.3
AK178
N, NA, stage:NA, dead, 240 days
16.1
AK091
N, NA, stage:NA, dead, 210 days
15.1
AK049
N, NA, stage:NA, dead, 180 days
14.0
AK003
N, NA, stage:NA, dead, 600 days
13.9
AK005
N, NA, stage:NA, dead, 240 days
13.2
AK236
N, NA, stage:NA, dead, 360 days
12.8
AK205
N, NA, stage:NA, dead, 120 days
12.7
AK055
N, NA, stage:NA, dead, 240 days
12.1
AK185
N, NA, stage:NA, alive, 330 days
11.5
AK072
N, NA, stage:NA, dead, 150 days
9.9
AK227
N, NA, stage:NA, alive, 300 days
9.3
AK051
N, NA, stage:NA, dead, 360 days
8.6
AK088
N, NA, stage:NA, dead, 360 days
7.0
AK079
N, NA, stage:NA, dead, 210 days
6.6
AK167
N, NA, stage:NA, dead, 180 days
6.0
AK074
N, NA, stage:NA, alive, 300 days
5.0
AK123
N, NA, stage:NA, dead, 180 days
5.0
AK139
N, NA, stage:NA, dead, 270 days
4.6
AK071
N, NA, stage:NA, dead, 540 days
4.5
AK149
N, NA, stage:NA, dead, 420 days
4.2
AK100
N, NA, stage:NA, alive, 960 days
4.0
AK158
N, NA, stage:NA, dead, 360 days
2.9
AK183
N, NA, stage:NA, alive, 360 days
2.7
AK142
N, NA, stage:NA, alive, 90 days
2.7
AK053
N, NA, stage:NA, dead, 300 days
2.6
AK134
N, NA, stage:NA, dead, 360 days
2.4
AK035
N, NA, stage:NA, dead, 210 days
2.3
AK173
N, NA, stage:NA, dead, 180 days
2.3
AK099
N, NA, stage:NA, dead, 420 days
1.9
AK002
N, NA, stage:NA, dead, 570 days
1.8
AK076
N, NA, stage:NA, alive, 660 days
1.2
AK216
N, NA, stage:NA, dead, 360 days
1.0
AK156
N, NA, stage:NA, dead, 330 days
1.0
AK231
N, NA, stage:NA, dead, 240 days
0.9
AK015
N, NA, stage:NA, alive, 720 days
0.9
AK102
N, NA, stage:NA, alive, 1740 days
0.8
AK103
N, NA, stage:NA, alive, 1320 days
0.8
AK165
N, NA, stage:NA, alive, 360 days
0.7
AK068
N, NA, stage:NA, alive, 360 days
0.6
AK066
N, NA, stage:NA, alive, 960 days
0.5
AK043
N, NA, stage:NA, alive, 660 days
0.4
AK199
N, NA, stage:NA, alive, 1860 days
0.4
AK085
N, NA, stage:NA, alive, 660 days
0.4
AK124
N, NA, stage:NA, alive, 1920 days
0.3
AK041
N, NA, stage:NA, alive, 810 days
0.3
AK213
N, NA, stage:NA, alive, 2010 days
0.2
Show allShow less
GLIOBLASTOMA MULTIFORME - Protein relative expression (CPTAC)
Number of samples
110
Samples
Sample ID
Sample type
nRPX
CPT0205570003
Tumor
2.4
CPT0123530003
Tumor
2.2
CPT0217000004
Tumor
2.0
CPT0204360003
Normal
1.9
CPT0127420003
Tumor
1.9
CPT0093450003
Tumor
1.5
CPT0162100003
Tumor
1.4
CPT0204410003
Normal
1.4
CPT0217430008
Tumor
1.3
CPT0204370003
Normal
1.1
CPT0182500003
Tumor
0.9
CPT0189460003
Tumor
0.9
CPT0162020003
Tumor
0.9
CPT0093360003
Tumor
0.8
CPT0064650003
Tumor
0.8
CPT0171580008
Tumor
0.8
CPT0168830003
Tumor
0.8
CPT0224540004
Tumor
0.7
CPT0204340003
Normal
0.7
CPT0206670004
Tumor
0.5
CPT0206110003
Tumor
0.5
CPT0206880003
Tumor
0.5
CPT0093550003
Tumor
0.5
CPT0125570003
Tumor
0.5
CPT0224600003
Tumor
0.4
CPT0216920008
Tumor
0.4
CPT0217060003
Tumor
0.4
CPT0189650004
Tumor
0.4
CPT0218330004
Tumor
0.3
CPT0218690004
Tumor
0.3
CPT0087950003
Tumor
0.2
CPT0161730003
Tumor
0.1
CPT0206450003
Tumor
0.1
CPT0087680003
Tumor
0.0
CPT0002410011
Tumor
0.0
CPT0167530003
Tumor
0.0
CPT0219080004
Tumor
0.0
CPT0092440003
Tumor
-0.1
CPT0078580003
Tumor
-0.1
CPT0168380003
Tumor
-0.1
CPT0064890003
Tumor
-0.1
CPT0087730003
Tumor
-0.1
CPT0225730003
Tumor
-0.1
CPT0168270003
Tumor
-0.1
CPT0206780003
Tumor
-0.2
CPT0167970003
Tumor
-0.2
CPT0221180003
Tumor
-0.2
CPT0167860004
Tumor
-0.3
CPT0228220003
Tumor
-0.3
CPT0079790003
Tumor
-0.3
CPT0204330003
Normal
-0.3
CPT0071100003
Tumor
-0.4
CPT0204420003
Normal
-0.4
CPT0208980003
Tumor
-0.4
CPT0206000004
Tumor
-0.4
CPT0205450004
Tumor
-0.4
CPT0186100003
Tumor
-0.4
CPT0089150003
Tumor
-0.4
CPT0205780003
Tumor
-0.4
CPT0196850003
Tumor
-0.5
CPT0087570003
Tumor
-0.5
CPT0125220003
Tumor
-0.5
CPT0190360004
Tumor
-0.5
CPT0205670004
Tumor
-0.5
CPT0218890004
Tumor
-0.5
CPT0167750004
Tumor
-0.6
CPT0175060003
Tumor
-0.6
CPT0205890003
Tumor
-0.6
CPT0206230003
Tumor
-0.6
CPT0189850004
Tumor
-0.6
CPT0167640003
Tumor
-0.7
CPT0206560003
Tumor
-0.7
CPT0209440003
Tumor
-0.7
CPT0217100003
Tumor
-0.7
CPT0217710008
Tumor
-0.7
CPT0199770003
Tumor
-0.7
CPT0127480003
Tumor
-0.7
CPT0168590003
Tumor
-0.7
CPT0182550003
Tumor
-0.7
CPT0168480003
Tumor
-0.8
CPT0218960004
Tumor
-0.8
CPT0168080003
Tumor
-0.8
CPT0168720003
Tumor
-0.8
CPT0093590003
Tumor
-0.9
CPT0189250003
Tumor
-0.9
CPT0217880003
Tumor
-0.9
CPT0218770003
Tumor
-0.9
CPT0225760003
Tumor
-0.9
CPT0104220003
Tumor
-0.9
CPT0217190003
Tumor
-0.9
CPT0093510003
Tumor
-1.0
CPT0189570004
Tumor
-1.0
CPT0207030003
Tumor
-1.0
CPT0182580003
Tumor
-1.0
CPT0190240004
Tumor
-1.0
CPT0125510003
Tumor
-1.1
CPT0204380003
Normal
-1.2
CPT0206330003
Tumor
-1.2
CPT0224390004
Tumor
-1.2
CPT0189750004
Tumor
-1.2
CPT0162140003
Tumor
-1.2
CPT0218830004
Tumor
-1.2
CPT0104330003
Tumor
-1.3
CPT0207090003
Tumor
-1.4
CPT0204390003
Normal
-1.4
CPT0204350003
Normal
-1.5
CPT0201710003
Tumor
-1.5
CPT0218670003
Tumor
-1.5
CPT0224330003
Tumor
-1.6
CPT0204400003
Normal
-1.7
Show allShow less
GLIOMA - Protein expressioni
A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.
Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.